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Members of the ADAM (A Disintegrin And Metalloprotease) protein family 
uniquely exhibit both proteolytic and adhesive properties.  Specifically, ADAMs catalyze 
the conversion of cell-surface proteins to soluble, biologically active derivatives through 
a process known as ectodomain shedding.  Ectodomain shedding coordinates normal 
physiological processes.  Aberrant ADAM activity contributes to pathological states, 
such as chronic inflammation.  Understanding how ADAM ectodomain shedding activity 
is governed may provide new avenues for therapeutic intervention of ADAM-mediated 
shedding pathologies. 
While ectodomain shedding is the hallmark feature of the ADAMs, thirteen of the 
forty ADAMs identified among various species are catalytically inactive.  Noncatalytic 
ADAMs lack one or more consensus elements (HExxHxxGxxH) within the active site of 
the metalloprotease domain.  Despite lacking the hallmark catalytic activity, noncatalytic 
ADAMs exhibit function(s) associated with other nonenzymatic domains (e.g. integrin 
 recognition of the disintegrin domain).  Disruption/mutation of noncatalytic ADAMs has 
been associated with perturbation of biological events.   
My overall hypothesis is that noncatalytic ADAMs regulate the activity of 
catalytically active ADAMs by competing for substrates and/or receptors when 
expressed within the same cellular niche.  To begin testing this proposed competitive 
binding regulatory mechanism, I used noncatalytic human ADAM7 and catalytically 
active human ADAM28 as a model ADAM pair.  Preliminary, unpublished data from our 
lab demonstrated expression of ADAM7 mRNA in multiple immune cell lines established 
to express ADAM28 at the protein level.  For determination of ADAM7 expression 
patterns, monoclonal antibodies against ADAM7 were produced by our lab.  However, 
the antibodies failed to exhibit reactivity against exogenous, full-length ADAM7.  
Based upon preliminary phylogenetic analysis and genomic location, it is likely 
that ADAM7 arose from gene duplication of ADAM28, which would allow a genetic copy 
of the molecular specificity required for regulation (e.g. integrin binding) with eventual 
silencing of catalytic activity.  We predicted that the gross structural integrity of the 
metalloprotease may be uniquely conserved between ADAM7 and ADAM28.  
Restoration of the active site glutamate residue of the ADAM7 metalloprotease domain 
bestowed catalytic activity to ADAM7 in a manner that reflected specificity of ADAM28-
mediated catalysis. This is the first demonstration, to our knowledge, of “awakening” a 
noncatalytic enzyme through a single point mutation.  This discovery provides an initial 
functional link between ADAM7 and ADAM28 and lends credence to the hypothesis that 
ADAM7 may regulate ADAM28 through competitive binding.  These findings have a 
broader impact, as 92 of the 570 collective human proteases are noncatalytic.  
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Introduction 
 ADAMs (A Disintegrin And Metalloprotease) are members of the Adamalysin 
subfamily of metzincin metalloproteinases (Gromis-Rüth, 1993), but they are unique 
compared to other proteases in that they also exhibit adhesive properties (Edwards, 
2008).  Currently, 40 total ADAMs have been identified across many species, ranging 
from yeast (Schizosaccharomyces pombe) and nematodes (Caenorhabditis elegans) to 
vertebrate animals such as Xenopus laevis and humans (Huxley-Jones, 2007).  
Irrespective of the species, each ADAM is expressed as a zymogen consisting of a 
prototypical multidomain architecture.  Listed from N-terminus to C-terminus, the 
domains are: Pro-domain, Metalloprotease domain, Disintegrin domain, Cysteine-rich 
domain, EGF domain, transmembrane domain, and the Cytoplasmic domain (Fig 1) 
(Weber, 2012).  The hallmark feature of the ADAM family is ectodomain shedding, 
which is the cleavage of cell surface substrates into soluble, biologically active 
derivatives (Fig 2).  
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Figure  1.  Prototypical ADAM Domain Architecture.  Depicted are the multiple, 
functional domains typical of the ADAM protein family.  Multi-domain architecture is 
conserved across catalytically active and noncatalytic ADAMs.  Soluble ADAM 
isoforms that arise from alternative splicing of selective members terminate following 
the EGF domain.  Conserved N-glycosylation sites important for structure and function 
are displayed as branches extending from the ADAM structure. 
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Figure 2. ADAM-mediated Ectodomain Shedding.  Catalytically active ADAM28 
processes membrane-bound TNF-α into soluble TNF-α (sTNF- α).  sTNF- α is freely 
diffusible and able to bind TNF-Receptor I (TNF-RI) on the same cell surface or an 
adjacent cell.  Binding of sTNF- α to TNF-RI stimulates signaling cascades to promote 
inflammation (Jowett, 2012).  
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ADAM Domains  
 The N-terminal pro-domain is responsible for maintaining latency of catalytic 
activity through a cysteine switch mechanism (Loechel, 2002; Milla, 2006; Roghani, 
1999; Smith and DeSimone, 2002).  The cysteine switch prohibits zinc coordination 
within the catalytic active site to prevent catalysis.  Latency is maintained by the 
cysteine switch through steric obstruction of the active site and coordination of Zn2+ via 
a conserved cysteine residue within the pro-domain that positions the sulfur of its side-
chain in close proximity of Zn2+ within the active site (Loechel, 1999).  A similar 
regulatory strategy is exhibited by Matrix Metalloproteases (MMPs), a family of 
metzincin proteases similar to the ADAMs (Bode, 1993).  Removal of the pro-domain 
occurs in the trans-Golgi network during post-translational processing by self-activation 
of the metalloprotease domain (Lum, 1998; Schlomann, 2002) or by the action of 
proprotein convertases such as furin proteases (Lum, 1998).  In addition to maintaining 
latency of the catalytic active site, the pro-domain acts as a chaperone post-
translationally by aiding folding and trafficking of the ADAM prior to being removed 
(Roghani, 1999).  
The metalloprotease domain is responsible for ectodomain shedding of 
substrates, which occurs via nucleophilic attack of the peptide backbone of peptide 
substrates (Fig 3).  The active site within the metalloprotease domain contains a 
consensus sequence (HExxHxxGxxH) that is indicative of metal ion coordination and 
nucleophilic attack of the peptide substrates (Bode, 1993).  The achiral nature of glycine 
allows for a turn within the structure of the active site, providing the necessary flexibility 
required for positioning the three histidine residues required for zinc coordination (Fig 
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4).  Zinc plays a role in coordinating water molecules to the active site.  The 
deprotonated carboxylic acid side chain of glutamate acts as a nucleophile, extracting a 
proton from water molecules coordinated to the Zn2+ metal center.  The deprotonated 
water molecule then acts as a nucleophile toward a carbonyl carbon of the peptide 
backbone of the target substrate (Gromis-Rüth, 2003).  A conserved methionine turn 
within the catalytic domain, a characteristic feature of metzincin proteases, is highly 
conserved among the ADAMs and is thought to play a role in zinc coordination (Bode, 
1993).  X-ray crystallographic studies of SVMPs, VAP1 and VAP2B, have revealed 
much of what is known about the structure of the metalloprotease domain (Igarashi, 
2007; Takeda, 2006).  The metalloprotease domain consists of two distinct subdomains, 
with the catalytic active site positioned within a cleft created by the subdomains.  The N-
terminal subdomain is composed of four α-helices and a highly twisted five-stranded β-
sheet.  The lower subdomain is composed of a single α-helix and an unevenly folded 
portion, which is involved in recognition of substrates (Takeda, 2009).   
While metalloprotease function is one of the most defining and salient aspects of 
the ADAM family, nearly half of the human ADAMs lack one or more of the consensus 
sequence elements required for catalytic activity (Wei, 2011).  However, these 
noncatalytic ADAMs still exhibit the overall domain architecture of a prototypical ADAM 
(Fig 1) (Liu, 2009).  Biological implications of these noncatalytic ADAMs have begun to 
emerge in the literature as a result of investigating expression knockdown or protein 
mutations.  Mutations in ADAM7 have been linked to increased metastasis of melanoma 
cells, which is speculated to be a result of decreased adhesion of extracellular matrix 
components, such as collagen IV and laminin-1 (Wei, 2011).  Despite these studies, the 
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biological significance of these fairly abundant “dead” sheddases is still poorly 
understood.   
The list of ADAM substrates is vast and encompasses molecules such as 
cytokines, growth factors, growth factor receptors, and GPCR ligands (Hartmann, 
2013).  ADAM-mediated shedding has been implicated in the coordination of many 
physiological processes, including embryonic development and immune response.  One 
example is the shedding of neuregulin via ADAM19, which has been documented to 
play a crucial role in cardiac development (Zhou, 2004).  Additionally, Tumor Necrosis 
Factor-α (TNF-α) shedding via ADAM28 (Jowett, 2012) results in a pro-inflammatory 
signaling cascade during immune response, excess shedding of which has been 
implicated in chronic inflammation.  While these processes involve many additional 
signaling events and molecular interactions, ADAM-mediated shedding plays a vital role 
in many physiological events.  
As ADAM proteolytic action is required for many critical events from development 
into adulthood, dysregulation of ADAM-mediated shedding can be deleterious.  ADAM-
mediated shedding of biologically decisive molecules, such as growth factors and 
cytokines, place ADAMs at the interface of health and disease (Klein, 2010; Weber, 
2012).  For example, while TNF-α shedding, cleavage of the TNF-α ectodomain into a 
biologically active form, plays a role in the normal health state, excess shedding of TNF-
α by ADAM17 has been implicated in chronic inflammatory states, such as rheumatoid 
arthritis (Klein, 2010).  Additionally, increased levels of soluble TNF-α can lead to 
increased transcription of ADAM17 (Bzowska, 2004), compounding and further 
promoting the inflammatory state in a vicious cycle.  Excess shedding of heparin-
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binding epidermal growth factor (HB-EGF) via ADAM12 has been implicated in cardiac 
hypertrophy (Asakura, 2002), a condition that can result in cardiac failure and eventually 
death.  As these examples illustrate, dysregulation of ADAM-mediated shedding can 
play a role in pathological conditions, many of which lack efficient treatment.  An 
enhanced understanding of how ADAM-mediated shedding is regulated is absolutely 
crucial to developing new avenues of treatment for a spectrum of disease states. 
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Figure 3.  Nucleophilic Attack Of a Peptide Substrate.   Zinc, coordinated by 
three histidine residues, coordinates water molecules to the metal center within the 
active site.   Glutamate deprotonates water.  The deprotonated oxygen of water acts 
as a nucleophile toward the carbonyl carbon of the peptide backbone of the 
substrate, resulting in cleavage at the scissile bond.  
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Figure 4.  ADAM Metalloprotease Domain Catalytic Active Site.  ADAM28 catalytic 
active site modeled on the catalytic active site of ADAM33.  The catalytic active site in 
the metalloprotease domain possesses a consensus sequence (HExxHxxGxxH) 
indicative of catalytic activity.  Glycine provides a structural turn, allowing the three 
histidine residues (represented in blue) to coordinate Zn
2+
 (represented by the green 
sphere) within the active site.  Glutamate (represented in red) is required for 
nucleophilic attack.  
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 The disintegrin domain provides a means for integrin receptor recognition by 
ADAMs.  The integrin ligand properties of ADAMs have been reported to facilitate cell-
cell and cell-matrix interactions and promote cell migration (White, 2003).  In fact, a 
significant amount of overlap exists among the ADAMs with respect to integrin 
recognition and interaction.  For example, seven different ADAMs (ADAM2, ADAM3, 
ADAM7, ADAM12, ADAM19, ADAM28, and ADAM33) serve as integrin α4β1 ligands 
(Arribas, 2006).  Despite the overlapping integrin ligand specificities, studies 
investigating whether ADAMs compete for integrin occupancy are lacking.  Preliminary 
unpublished work from our lab is the first to demonstrate that the ADAM disintegrin 
domains selectively compete for integrin receptor binding (Fig 5).   
The concept that ADAMs compete for integrin receptors is novel and forms the 
basis for our regulatory model (Fig 6).  By exhibiting competition for integrin receptor 
occupancy, it is highly plausible these ADAMs compete for additional substrates using 
their nonenzymatic domains.  In fact, competitive binding of substrates in this manner 
may govern the availability of substrates, which is the basis of the proposed regulatory 
role. 
  In addition, emerging evidence in the literature indicates that the nonenzymatic 
domains (disintegrin and cysteine-rich domains) of the ADAM family confer specificity to 
the metalloprotease domain (Smith and DeSimone, 2002; Xu, 2010; Sadler E., 2009; 
Stawikoska, R., 2013) and that integrin recognition is critical in governing ADAM17-
mediated shedding (Gooz, 2012).  Given these studies demonstrating the importance of 
the disintegrin and cysteine-rich domains to ADAM-mediated shedding, the presence of 
catalytically inactive ADAMs that exhibit adhesive properties indicates the potential for  
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similar interactions that may play a role in regulating substrate availability.  However, no 
explorations into how these formative findings relate or apply to the appreciable number 
of noncatalytic ADAMs have been reported.   
 In addition to the adhesive properties of the disintegrin domain, the cysteine-rich 
domain aids adhesion to extracellular matrix (ECM) components.  In fact, this function is 
independent of disintegrin-integrin interactions (Klein, 2010).  A key, defining feature of 
the cysteine-rich domain is the hypervariable region (HVR), which is speculated to play 
a role in recognition of substrates important to cell-cell and cell-matrix interactions 
(Takeda, 2006; Igarashi, 2007).  This has led to speculation that the cysteine-rich 
domain works concomitantly with the disintegrin domain to confer specificity to the 
metalloprotease domain (Takeda, 2006).   
 The EGF domain is the C-terminal end of the ectodomain.  While the EGF 
domain function has not been determined, it is thought to act as a spacer to maintain 
distance from the cell surface and other extracellular domains to facilitate interactions 
with substrates and receptors.  Following the EGF domain is the transmembrane 
domain, anchoring the protein to the cell surface.  Transcription of soluble ADAM 
isoforms (e.g. ADAM8, ADAM9, ADAM12, ADAM28, and ADAM33) is terminated 
following the EGF domain via alternative splicing (Klein, 2011).  
 The cytoplasmic domain is the only intracellular domain and is the site of the 
most variation in length and protein sequence among the ADAMs (Seals and 
Courtneidge, 2003; Takeda, 2006).  The cytoplasmic domain contains putative 
phosphorylation sites for serine-threonine and tyrosine kinases, as well as providing 
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potential binding sites for SH3 and SH2 domain-containing proteins (Howard, 1999). 
Interestingly, intracellular interactions involving the cytoplasmic domain have been 
shown to play a role in regulating the specificity of shedding activity exhibited by the 
metalloprotease domain (Xu, 2010).  The work by Xu et al. provides additional evidence 
that nonenzymatic domains and their respective molecular interactions serve to modify 
activity of the metalloprotease domain, and therefore, embody a potential regulatory 
mechanism.  Due to the diversity exhibited within the cytoplasmic regions of ADAMs, we 
do not posit that noncatalytic ADAMs regulate shedding by competing for cytosolic 
binding partners.  However, the possibility of competition for cytosolic binding partners 
will be addressed by the Bridges lab in future cell-based experiments. If noncatalytic 
ADAMs do govern shedding activity, inside-out signaling, in which an intracellular 
signaling event produces an extracellular effect, involving their cytoplasmic domain 
could potentially play a role in their ability to interact with substrates via the 
metalloprotease domain.  
Regulation of ADAM-Mediated Shedding 
 Established mechanisms for regulating shedding include the modulation of 
ADAM transcription, the removal of the pro-domain, trafficking of ADAMs within the cell 
and escort to secretory pathways, and removal of ADAMs from the cell surface via 
endocytosis (Reviewed by Hartmann, 2013) (Table 1).  Additionally, phosphorylation of 
the cytoplasmic tail has been shown to activate shedding via inside-out signaling (Xu, 
2010).  Binding of substrate with the disintegrin or cysteine-rich domain can also play a 
regulatory role.  For example, the cysteine-rich domain is required for shedding of IL-1 
Receptor-II by ADAM17 (Reddy, 2000).  Interaction of the disintegrin domain with 
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integrins comprises an alternate mechanism of regulation.  An example of integrin-
ADAM interaction affecting shedding is the subsequent decrease and inhibition of 
shedding activity by ADAM17 (Gooz, 2012).   
 However, regulation is not limited to the enzyme level.  Only a small, select group 
of catalytically active ADAMs is responsible for shedding a large number of diverse 
substrates (Huovila, 2005).  Therefore, it seems reasonable that regulation also occurs 
at the level of substrate (Hartmann, 2013).  Regulatory mechanisms may include post-
translational modification and conformational change.  Another example of substrate 
modification impacting catalytic activity is the binding of Notch receptor with ligand, 
which is required for ADAM10-mediated shedding of the Notch1 receptor ectodomain 
(Bozkulak, 2009).   
The regulatory mechanisms emerging in the literature provide a relevant context 
in which to finally address the biological role of noncatalytic ADAMs.  Specifically, the 
nonenzymatic domains (disintegrin and cysteine-rich domains) of a catalytically active 
ADAM demonstrating a role in specificity and co-localization to facilitate shedding 
provides a glimpse into the potential function of noncatalytic ADAMs.  We believe the 
nonenzymatic domains of noncatalytic ADAMs may serve a similar role through 
interactions with substrates typically shed by their catalytically active counterparts.   
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Table 1. Regulatory Mechanisms of Shedding 
Mechanism Identified Cellular Consequence Reference 
Removal of pro-
domain 
Activation of metalloprotease domain 
Roghani, 1999; 
Lum, 1998;  
Modulation of 
transcription 
Apoptosis, cell proliferation, cancer 
progression 
Mochizuki, 2007 
Removal from cell 
surface 
Decreased shedding, altered signaling, 
disrupted substrate function 
Carey, 2011 
Phosphorylation of 
cytoplasmic tail 
Cell proliferation, cancer progression, and 
chronic inflammation 
Xu, 2010 
Substrate 
conformational 
change 
Notch1 conformational change exposing 
cleavage site and facilitating selective 
cleavage to activate transcription  
Bozkulak, 2009 
Unknown 
Noncatalytic ADAMs govern substrate 
availability via competitive binding 
Hypothetical Model 
for Current Thesis 
Proposal 
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Noncatalytic ADAMs  
 As with the ADAM field at large, the introduction has predominantly focused on 
the catalytic action of ADAM sheddases.  However, 8 of the 21 human ADAMs are 
noncatalytic (Edwards, 2008) (Table 2). These ADAMs are defined by lacking one or 
more consensus elements (HExxHxxGxxH) within the catalytic active site.  Despite 
missing these elements, they still possess the prototypical multi-domain architecture of 
their catalytically active counterparts (Liu, 2009).  In spite of their prevalence, the 
biological relevance of ADAMs that lack hallmark sheddase activity is not well 
understood. 
 While the metalloprotease domain of the noncatalytic ADAMs does not exhibit 
catalytic activity, the noncatalytic domains exhibit function (e.g. integrin recognition) and 
select noncatalytic ADAMs have newly identified roles in biological processes.  For 
example, ADAM23, a noncatalytic ADAM, has been implicated in axon guidance and 
neural connectivity during normal embryonic development (Leighton, 2001), as well as 
modulating activation of integrin ανβ3 (Verbisk, 2009) through its noncatalytic domains.  
ADM-1, a noncatalytic ADAM expressed in C. elegans, has also been implicated in 
neuron axon guidance, a function attributed to its nonenzymatic domains (Huang, 
2003).  Disruption of noncatalytic ADAMs has also been associated with pathological 
states.  Mutations in the ADAM7 gene have been implicated in increased cell migration 
and metastasis of melanoma cells as a result of the decreased ability of ADAM7 to bind 
laminin-1 and collagen IV (Wei, 2011).   
20 
 
 Although these studies attest to the biological relevance of noncatalytic ADAMs, 
they comprise only a few examples of their functional relevance.  Based upon the 
frequency of noncatalytic ADAMs across all species (33%), one might expect an 
equivalent amount of articles would describe studies involving a noncatalytic ADAM.  
However, only 69 out of 1,039 (6.6%) articles retrieved via PubMed search of primary 
articles containing ADAM nomenclature in the title investigated noncatalytic ADAMs.  
 Because they are severely understudied, it is likely that noncatalytic ADAMs are 
exerting biological effects that have yet to be delineated.  What we believe, as is 
expanded on in my hypothesis, is that noncatalytic ADAMs may play a role in regulating 
the activity of their catalytically active counterparts by governing access to or availability 
of substrates.  This novel functional paradigm is supported by the fact that: i) a 
particular ADAM’s noncatalytic domains contribute to catalytic activity and/or specificity 
of that specific ADAM, ii) both catalytically and non-catalytically active ADAMs contain 
the prototypical domains, possibly allowing for the same molecular interactions to occur, 
and iii) our preliminary data suggest that there is select competition between catalytic 
and noncatalytic ADAMs for receptor occupancy (Fig 5).  
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Table 2. Noncatalytic ADAMs Expression Patterns and Roles in Health and Disease 
Gene Expression 
Normal Health 
Roles 
Pathological 
Implications* 
Consensus Sequence** 
ADAM2 Testis 
Sperm-egg 
interaction 
Lung 
Carcinoma 
QLLSLSMGITYD 
ADAM7 
Testis, 
Erythrocytes 
Cell-cell and cell-
matrix interaction 
Hepatic 
Carcinoma, 
Melanoma 
metastasis 
HQLGHNLGMQHD 
ADAM11 
Erythrocytes, 
Central & 
Peripheral 
Nervous 
Systems, 
Liver 
Spatial learning, 
Motor 
coordination 
Impaired 
spatial 
learning, 
Altered 
nociception 
QTLGQNLGMMWN 
ADAM18 
Testis, 
Erythrocytes, 
Bone 
marrow, 
Pancreas 
Spermatogenesis, 
Fertilization 
CNS Glioma, 
Malignant 
Melanoma 
QLLGLNVGLTYD 
ADAM22 
Central & 
Peripheral 
Nervous 
System 
Mediates growth 
inhibition 
Epilepsy, 
Peripheral 
neuropathy 
 
ADAM23 
Central & 
Peripheral 
Nervous 
System, 
Heart 
Axon guidance, 
neural 
connectivity 
Promotion of 
metastasis 
QSLAQNLGIQWE 
ADAM29 Testis 
Spermatogenesis, 
Fertilization 
Malignant 
Melanoma, 
CNS Glioma 
HHLGHNLGMNHD 
ADAM32 
Testis, Blood 
lymphoid 
cells 
Sperm-egg 
interaction 
Hepatic 
Carcinoma 
QMLALSLGISYD 
* Resulting from aberrant expression and/or mutations 
**Consensus sequence of catalytically active ADAMs: HExxHxxGxxH 
22 
 
 
 
 
 
 
 
 
 
 
23 
 
 
 
 
 
 
 
 
 
Figure 5.  Competitive Binding of ADAM Disintegrin Domains.  Soluble 
disintegrin domains of ADAM7, ADAM9 and ADAM15 were utilized in the presence of 
immobilized ADAM28 to investigate competitive binding of integrin receptors.  
ADAM7 alone competitively inhibits integrin-mediated adhesion to ADAM28 (blue 
bar).  ADAM9 and ADAM15 did not result in a statistically significant difference in 
integrin-mediated cell adhesion to ADAM28 (white bars).  Asterisks denote statistical 
significant (p<0.01) using one-way ANOVA with a Tukey’s post-hoc test.   Error bars 
represent standard error from the mean.  Preliminary data obtained by the Bridges 
lab.  
 
 
Hypothesis 
 As it is becoming apparent that nonenzymatic domains of catalytically active 
ADAMs contribute to regulation of shedding, noncatalytic ADAMs may potentially 
function in a similar manner.  As the noncatalytic ADAMs can facilitate similar molecular 
interactions as catalytically active members, our lab’s long-term hypothesis is that 
noncatalytic ADAMs govern ADAM-mediated shedding by competitively binding 
substrates and/or receptors (Fig 6).  To begin determining whether this proves to be 
true, I have focused on investigating the structural preservation of the catalytic active 
site within the metalloprotease domain of noncatalytic ADAMs.  My hypothesis, specific 
for my thesis studies, is that restoration of consensus elements within the active site of 
the metalloprotease domain via a single point-mutation will bestow catalytic activity, and 
specificity, to ADAM7 as is exhibited by its catalytically active counterpart, ADAM28.  
The “awakening” of catalytic activity would indicate the gross structural preservation of 
the catalytic active site in noncatalytic ADAMs. 
 Based upon this model, I posit that noncatalytic ADAMs arose from catalytic 
ADAM ancestors through gene duplication events.  This would allow a genetic copy of 
the molecular specificity required for regulation (e.g. integrin binding) with eventual 
silencing of the catalytic activity by elimination of consensus site elements.  The current 
work addresses the validity of the novel regulatory model by determining: i) catalytic and 
noncatalytic ADAMs exhibit an overlapping expression pattern to allow for competition 
and ii) that noncatalytic ADAMs possess remnants of catalytic activity.  This study seeks 
to determine the preservation of the catalytic active site of noncatalytic ADAMs, as well 
as expression patterns of noncatalytic and catalytically active ADAM counterparts within 
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the same cellular niche.  Results from my study are aimed at defining a novel function of 
noncatalytic ADAMs by providing the first evidence that noncatalytic ADAMs serve as 
regulators of ADAM-mediated shedding. 
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Figure 6.  Proposed Regulatory Role for Noncatalytic ADAMs.  A)  Catalytically 
active ADAMs are free to bind receptors and shed substrates in the absence of a 
noncatalytic competitor.  B)  A noncatalytic ADAM binds an integrin receptor 
preventing the localization of a catalytically active ADAM to substrate.  In contrast to 
panel A, competition between ADAMs prevents shedding.   
 
 
Approach and Model System (ADAM28 and ADAM7)  
To investigate my hypotheses, I used ADAM28 and ADAM7 as a model pair.  
Genes for both reside within a single cluster on human chromosome 8p21.2 (Bates, 
2002), indicating ADAM7 may have arisen from gene duplication events of ADAM28.  
ADAM28 has previously been shown to be expressed at the protein level on the surface 
of many immune cell lines, including THP-1 monocytes and various B-lymphomas 
(McGinn, 2011).  ADAM28, expressed as a 115kDa zymogen, is self-activated (Howard, 
2000) and exists as an 88kDa protease in its mature form on the cell surface.  In 
addition to expression on cell surfaces, ADAM28 is expressed as a soluble isoform due 
to alternative splicing.  ADAM28 has been implicated in many physiological processes, 
including aiding transmigration of lymphocytes via integrin interactions (McGinn, 2011).  
Pathologically, excess ADAM28-mediated TNF-α shedding plays a role in chronic 
inflammation (Jowett, 2012), in states such as rheumatoid arthritis, and also has been 
implicated in osteoarthritis via the degradation of proteoglycans when expressed on the 
surface of chondrocytes (Hikichi, 2009). Additionally, ADAM28 has also been implicated 
in cell proliferative processes through the shedding of insulin-like growth factor binding 
protein-3 (IGFBP-3) of the IGFBP-3/IGF-1 complex (Mochizuki, 2004; Mitsui, 2006; 
Ohtsuka, 2006). 
While much is known about ADAM28, very little is known about ADAM7.  
Previously, ADAM7 was found in human seminal fluid and speculated to be secreted by 
the epididymis (Sun, 2000).  At the mRNA level, ADAM7 has been shown to be 
expressed and mutated in melanoma cells, in which cell adhesion is reduced aiding 
metastasis (Wei, 2011).  In addition to its suggested role in melanoma cells, ADAM7 
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has been widely considered as a fertility-centric protein based on murine studies with a 
potential role in the docking of egg with sperm via integrin-disintegrin interactions on the 
cell surface (Han, 2010).   
Preliminary data obtained in our lab, by JianMing Chen, has established that 
ADAM7 mRNA is expressed in many of the same immune cell lines previously 
demonstrated to express ADAM28 (Fig 7).  While the presence of mRNA does not 
always result in protein expression, the preliminary data is suggestive of a potential 
overlap in expression that could allow competition of ADAM7 and ADAM28 within those 
cells and niches.  The protein sequence of ADAM28 and ADAM7 displays a very high 
degree of homology within the disintegrin domain (67% identical, 76% similar), and 
these two ADAMs interact with the same integrin receptors (Bridges, 2005).  
Importantly, ADAM7 selectively inhibits integrin-dependent cell adhesion to ADAM28 
(Fig 5). Analysis of the consensus sequence within the metalloprotease active site 
shows ADAM7 differs by only a single residue, as it possesses a glutamine instead of 
the consensus glutamate (Fig 8).  Given these similarities, I believe ADAM28 and 
ADAM7 are the ideal model pair for investigation of this proposed regulatory 
mechanism.   
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Figure 7.  Preliminary ADAM7 mRNA Expression Patterns.  Immune cell lines were 
investigated for ADAM7 mRNA expression via Reverse Transcriptase (RT)-PCR.  
Intron-spanning primers were utilized to discriminate products derived from genomic 
contamination.  All products corresponded to amplification of cDNA templates and 
bands were sequence-verified to confirm the identity of ADAM7.   Data obtained by 
JianMing Chen.  
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Figure 8.  ADAM7 and ADAM28 Active Site Alignment.  Alignment of the human 
ADAM28 and ADAM7 active site sequence.  The consensus sequence is highlighted 
by the blue box.  Shaded grey residues are conserved between ADAM7 and ADAM28.  
ADAM7 possesses all but one consensus element (highlighted in red).   
 
 
Experimental Procedures 
Reagents  
 Lipofectamine LTX and Lipofectamine PLUS transfection reagents were 
purchased from Invitrogen.  Blasticidin-S was obtained from Corning.  Anti-Fc HRP 
antibody from Sigma Aldrich was used for detection of Fc-fusion protein.  Custom 
primers were ordered from Integrated DNA Technologies.  EZ-Link Sulfo-NHS Biotin 
was purchased from Thermo Scientific.  Catalytic activity and specificity assays used 
α2-Macroglobulin and myelin basic protein obtained from Sigma Life Sciences.  9e10 
antibody was kindly provided by Dr. Judith White.  Protein G Agarose Fast Flow resin 
and Immobilon PVDF membrane were obtained from Millipore.  Goat anti-mouse 
Human adsorbed FITC secondary antibody was purchased from Southern BioTech. 
Cell Culture 
High Five Insect cells were cultured in HyClone SFX-Insect Media (Fisher 
Scientific) supplemented with 1% penicillin-streptamycin and 0.1% gentamycin in a 
27°C environment.  CHO (Chinese hamster ovary) cell line was maintained in RPMI 
1640 media supplemented with 10% fetal bovine serum, 1% penicillin-streptamycin, and 
1% sodium pyruvate.  HEK293 (human embryonic kidney) cell line was maintained in 
DMEM supplemented with 10% fetal bovine serum, 1% penicillin-streptamycin, and 1% 
sodium pyruvate.  CHO and HEK293 cell lines were maintained at 37°C in a 5% CO2 
environment.   
 
35 
 
Cell-Surface Biotinylation 
HEK293 and CHO cells were transfected with a full-length ADAM7 construct in 
pCS2+ vector or empty pCS2+ vector, termed ‘mock’, for 48 hours.  Transfection of all 
cell lines was achieved with Lipofectamine LTX according to the manufacturer’s 
recommendations.  Following transfection, cells were washed twice in PBS (0.137M 
NaCl, 2.7mM KCl, 10mM Na2HPO4, 2mM KH2PO4), then incubated for 20 minutes in 
biotinylation buffer (PBS + 0.5μg/ml EZ-link NHS Biotin).  The cells were washed twice 
in PBS and detached with 5mM EDTA in PBS.  Detached cells were isolated via 
centrifugation at 1,000 rpm for 10 minutes at 4°C.  The cell pellet was resuspended and 
incubated in lysis buffer (PBS, 1% Triton-100 and 1:100 Roche protease inhibitor 
cocktail) with rocking for 1 hour at 4°C.  Cell surface proteins were isolated via 
centrifugation at 14,800 rpm for 10 minutes.  Supernatant was subsequently incubated 
with avidin agarose beads while rocking at 4°C overnight.  Beads were pelleted, 
supernatant decanted, and resin boiled in reduced SDS-PAGE sample buffer (500mM 
Tris-HCl pH 6.8, 10% SDS, glycerol, 2-β-mercaptoethanol, and 0.05% (w/v) 
bromophenol blue) prior to running on 10%/4% SDS-PAGE gel.  Separated samples 
were transferred to a PVDF membrane via horizontal current.  PVDF membrane was 
blocked for 1 hour at room temperature in 5% blotto (5% dry milk in PBST) with 
subsequent overnight incubation with the appropriate antibody (9e10 or ADAM7 mAb) 
at 4°C with agitation. Following overnight incubation at 4°C, the PVDF was prepared for 
development utilizing Advansta WesternBright ECL Kit. 
 
36 
 
Flow Cytometry 
HEK293 and CHO cells were transfected with a full-length ADAM7 construct in 
pCS2+ vector or empty pCS2+ vector for 48 hours and resuspended in FACS Buffer 
(PBS and 1% BSA) at 1x106 cells/ml.  Cells were incubated in the presence of ADAM7 
monoclonal antibodies for 30 minutes at room temperature.  Following application of the 
primary antibody, the cells were fixed in 0.37% formalin/PBS for 15 minutes.  The cells 
were then washed twice in FACS buffer and stained with goat anti-mouse human-
adsorbed IgG-FITC antibody for 15 minutes.  For analysis of fluorescence intensity, 
cells were resuspended in 300μl FACS buffer and run via FACScan flow cytometer.  
Results were analyzed using Cell Quest-Pro software.   
Production of Recombinant DNA Constructs Encoding ADAM ProMet-Fc 
DNA constructs were generated by extension of overlapping regions encoding 
the full pro-domain and metalloprotease domain of ADAM28 (Iso19 – Asp403) and 
ADAM7(Lys19 – His400) to a 5’ GP67 insect secretion signal and 3’ human IgG3 Fc 
affinity tag.  Following construct generation, PCR products were cloned into pIB/V5-His 
TOPO TA vector (Life Technologies) and sequence verified.   
QuickChange Mutagenesis of Human ADAM7 Pro-Met Construct 
Restoration of Glu337 within the catalytic active site was accomplished using 
QuikChange Mutagenesis PCR kit (Agilent Technologies).  Primers were used to 
introduce a single, point mutation resulting in the substitution of cytosine to guanine at 
the first position within the codon for Glutamine337 (5’-
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CAGAATGGCACATGAACTGGGGCATAAC-3’ and reverse primer 5'-
GTTATGCCCCAGTTCATGTGCCATTCTG-3'). 
Expression and Purification of Recombinant FC-fusion Protein 
Following sequence verification, High Five insect cells were transfected with 8μg 
of DNA constructs (ADAM28 PM-Fc wt, ADAM7 PM-Fc wt, and ADAM7 PM-Fc Q337/E) 
using Lipofectamine PLUS transfection reagent in a 100mm dish at 75% confluency.  72 
hours post-transfection, cells were selected for successful transfection using 80 μg/ml 
Blasticidin for 24 hours.  Blasticidin concentration was then lowered to 50 μg/ml for 
continued maintenance and protein production thereafter.  Protein-enriched medium 
was harvested and concentrated overnight with polyethylene glycol in dialysis tubing in 
PBS + 5mM EDTA (pH 7.4) at 4°C.  Concentrated medium was applied to a protein-G 
affinity resin column, washed, and eluted via 100mM citric acid (pH 3.0) as 1ml fractions 
into tubes containing 300μl 1M Tris (pH 9.0) and 5mM EDTA.  Eluted fractions were 
analyzed for the presence of protein, measuring absorbance at 280nm; protein-
containing fractions were pooled and dialyzed overnight in PBS + 1mM EDTA (pH 7.0).  
Dialyzed fractions were then further concentrated via Amicon 30K MWCO filters 
(Millipore) according to the manufacturer’s instructions.  Concentrated eluent was 
quantified via BCA assay to determine final protein concentration.   
α2-Macroglobulin Trapping Assays  
Using previously established assay conditions (Loechel, 1998), trapping assays 
utilizing α2-Macroglobulin (α2M) were used to investigate catalytic activity.  Individual 
reactions were set up with 0.5μg recombinant ADAM protein (ADAM28 PM-Fc wt, 
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ADAM7 PM-Fc wt, ADAM7 PM-Fc Q337/E) and 30μg human plasma α2-Macroglobulin.  
α2M buffer (100mM NaCl, 50mM Tris-HCl (pH 7.4), 10mM CaCl2, 0.02% Sodium Azide) 
was added to a final volume of 25μl.  Reactions were incubated at 37°C for 24 hours, 
prior to being denatured and reduced and run on 7.5%/4% SDS-PAGE gel at 150V for 
60 minutes.  Resolved bands were transferred to PVDF membrane, blocked in 5% 
blotto (5% dry milk in PBST) for 1 hour at room temperature, and incubated overnight in 
the presence of anti-Fc antibody at 4°C with agitation.  After extensive washing, the 
PVDF was prepared for development using Advansta WesternBright ECL Kit.  To 
determine the relative contribution of zinc or glutamate, the assay was repeated with 
indicated concentrations of these parameters (Fig 11B and 11C).   
Myelin Basic Protein Catalytic Specificity Assay 
Assays were adapted and optimized from established techniques (Howard, 
2001).  To establish catalytic specificity, 25μl reactions were prepared using 1.5μg 
soluble, recombinant ADAM protein (ADAM28 PM-Fc wt, ADAM7 PM-Fc wt, ADAM7 
PM-Fc Q337/E), consisting solely of the pro-domain and metalloprotease domain with a 
C-terminal Fc-fusion tag, in the presence of 6μg myelin basic protein in MBP Assay 
Buffer (0.1M Glycine, 0.1mM Tris-HCl, 10mM CaCl2, 0.5mM ZnCl2 (pH 7.4)).  Reactions 
were incubated at 37°C for 20 hours. Following incubation, reactions were denatured 
and reduced prior to being run on 15%/4% SDS-PAGE gel at 150V for 90 minutes.  
Upon completion of electrophoresis, the gel was washed 3x5 minutes in ultra-pure H2O 
and stained overnight in Imperial Stain (Thermo Scientific), after which the gel was 
destained in ultra-pure H2O for 5 hours.    
 
 
Results  
ADAM7 Monoclonal Antibodies Selectively React with Soluble ADAM7 Disintegrin 
Domain 
A key component of the proposed regulatory mechanism is the expression of 
noncatalytic ADAMs in the same niche as their catalytically active counterparts.  Our 
preliminary data demonstrated that ADAM7 mRNA is expressed in a manner that 
reflects patterns previously established for ADAM28 (Fig 7).  Unfortunately, ADAM7 
monoclonal antibodies are not commercially available or readily accessible to address 
the protein expression pattern of human ADAM7.  Therefore, our lab had hybridomas 
developed with the goal of detecting full-length ADAM7 on the cell surface of human 
primary B-cells, immortal lymphoma lines, and tumor samples previously shown to 
express ADAM28. 
Using a soluble ADAM7 disintegrin domain Fc-fusion protein (Dis-Fc) as the 
antigen, ten hybridoma lines were produced for our lab.  After testing reactivity of the 
newly developed ADAM7 monoclonal antibodies in ELISA, supernatant from the ten 
hybridoma lines was tested for reactivity toward soluble ADAM7 disintegrin domain 
using Western Blot (Fig 9).  To verify specificity toward ADAM7, each of the hybridoma 
lines were concurrently tested against soluble ADAM28 Dis-Fc protein.  Several of the 
hybridoma lines (PD-2, 4, 5, 6, 7, 9, and 10) exhibited the desired ADAM7-selectivity 
and were able to recognize denatured and reduced ADAM7 Dis-Fc protein.  As our 
ultimate goal is to identify the expression pattern of ADAM7 in various human immune 
40 
 
cells and cell lines through flow cytometry, I wanted to determine if the monoclonal 
antibodies were also able to recognize full-length ADAM7 natively expressed by cells.   
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Figure 9.  Selective Reactivity of ADAM7 Monoclonal Antibodies.  Soluble 
ADAM28 and ADAM7 Disintegrin domain (3 μg/lane) was utilized to verify reactivity 
and selectivity of ADAM7 monoclonal antibodies.  
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Recognition of Full-length ADAM7 Protein 
To assess if the antibodies could recognize full-length ADAM7 within a cell, I 
exogenously expressed human ADAM7 in HEK293 (human embryonic kidney) and 
CHO (Chinese hamster ovary) cell lines.  The full-length ADAM7 construct, cloned into 
pCS2+ vector, contained a C-terminal Myc tag for detection purposes.  Mock treatment 
consists of an empty pCS2+ vector.  As shown in Figure 10A, exogenous cell-surface 
ADAM7 was observed in transfected cells, but not in the mock treated cells.   
Initially, mock and ADAM7 transfected cells were analyzed for ADAM7 
expression via flow cytometry with various dilutions of ascites from the monoclonal 
hybridomas.  While a variety of conditions were tested, none produced shifts in 
fluorescent intensity correlating with ADAM7 expression (Fig 10B).  Although the 
antibodies failed to work in flow cytometry, we speculated that the epitope may only be 
accessible when the protein is denatured.  To test this possibility, cell surface proteins 
were selectively enriched from mock and transfected cells and analyzed under reducing 
conditions in an immunoblot.  Unfortunately, no distinct bands corresponding to ADAM7 
were observed when the cell surface proteins were immunoblotted (Fig 10C).  Despite 
having multiple cell lines successfully express exogenous ADAM7, the hybridoma 
supernatant did not exhibit the ability to discriminate between mock and ADAM7-
transfected cells in flow cytometry or immunoblot.  Ability of the ADAM7 monoclonal 
antibodies to react with purified recombinant full-length ADAM7 was not assessed.  
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Figure 10. ADAM7 Monoclonal Antibody Detection of Full-Length ADAM7 on 
the Cell Surface.  A)  The indicated cell lines were transfected with full-length 
human ADAM7 in the pCS2+ myc tag vector.  Isolation of cell surface proteins was 
performed with biotinylation and SA-agarose pull down.  Detection of myc-tag 
epitope with the mAb 9E10 was done to verify exogenous ADAM7 (~100 kDa).  B)  
Flow cytometry analysis of mock (left) and ADAM7-transfected (right) cells 
described in panel A with no primary antibody.  PD-3 (bottom), an ADAM7  
monoclonal antibody, was unable to detect full-length ADAM7 on the cell surface 
of transfected (green line) cells as compared to controls (filled histogram).   C)  
PD-10, an ADAM7 monoclonal antibody, was unable to detect a band 
corresponding to full-length ADAM7 in transfected and mock-transfected cells.  
Shown is a representative result for cell lines and hybridoma clones. 
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Single Point-Mutation Bestows Catalytic Activity to a Noncatalytic ADAM 
We speculate that ADAM7 arose from a gene duplication event of ADAM28 and 
the gross structural integrity of the catalytic domain of noncatalytic ADAMs has been 
preserved throughout these evolutionary events.  Indeed, noncatalytic ADAMs do not 
group together in a phylogenetic tree (Fig 11), lending credence to the idea that ADAM7 
and the other noncatalytic ADAMs arose from multiple evolutionary events and not from 
a single common ancestor (Brocker, 2009).  In light of our regulatory model (Fig 6), this 
would be an efficient way to mimic the molecular aspects of active counterparts but 
selectively eliminate the catalytic activity.  To investigate this, we wanted to determine if 
restoration of the missing catalytic active site elements would “awaken” a dead 
protease.   
The consensus glutamate within the ADAM7 catalytic active site was restored via 
a single point mutation (Fig 8).  This was accomplished by substituting a single 
nucleotide, cytosine, within the glutamine codon (CAA) to guanine.  Doing so provided 
the mutant ADAM7 with a fully restored consensus sequence within the metalloprotease 
domain.  Recombinant Pro-Met Fc-fusion proteins (PM-Fc) for ADAM28, ADAM7 wt, 
and the active site ADAM7 Q337/E mutant migrated at roughly 75kDa as expected when 
using reducing SDS-PAGE (Fig 12).  These recombinant proteins exhibited sufficient 
purity to conduct the necessary proteolytic assays. 
The α2M trapping assay was used to demonstrate catalytic activity of the ADAM7 
active site mutant.  α2M is a generic protease inhibitor that acts by covalently linking to 
the enzyme upon cleavage.  This covalent linkage results in a higher molecular weight 
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species that can be observed by a gel shift.  The presence of a higher molecular weight 
species is indicative of an active protease.   
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Figure 11.  Phylogenetic Classification of Human ADAMs.  The 21 human 
ADAMs are grouped into six distinct clades based on phylogenetic analysis.  
Noncatalytic ADAMs (designated with a red asterisk) are grouped with 
catalytically active ADAMs in multiple clades, suggesting they arose from a 
common, catalytically active ancestor.   
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Figure 12.  Purified Pro-Met Fc-Fusion Proteins.  Recombinantly produced and 
purified ADAM Pro-Met Fc-fusion proteins (3 μg/lane) were visualized by commassie 
staining.  ADAM28 PM wt, ADAM7 PM wt, and ADAM7 PM Q337/E are roughly 75 kDa 
as expected. 
52 
 
As expected, the positive control ADAM28 PM-Fc exhibited catalytic activity, 
whereas wild-type ADAM7 PM-Fc did not.  Excitingly, and as anticipated, the ADAM7 
Q337/E mutant exhibited catalytic activity as evidenced by higher molecular weight 
species at 150kDa (Fig 13A).  This is the first demonstration, to our knowledge, of a 
single point mutation within the active site bestowing catalytic activity to a noncatalytic 
ADAM.   
Effect of Glutamate and Zinc Concentration on Noncatalytic ADAM7 
While it appears that the catalytic activity exhibited by ADAM7 Q337/E is the result 
of the mutation incorporated into the active site, the possibility existed that catalytic 
activity may result from other variables within the environment.  Indeed, studies by M. 
Toney and J. Kirsch have demonstrated the ability to rescue enzymatic activity of an 
inactive mutant of aspartate aminotransferase simply through the addition of amines in 
solution (Kirsch, 1989; Kirsch, 1992).  
  If the catalytic function of noncatalytic ADAMs could be “activated” in localized 
environments, this could embody an unexplored aspect of how ADAM shedding activity 
is regulated, and suggest noncatalytic ADAMs are active in vivo given the right 
conditions.  Specifically, glutamate and zinc within the environment were investigated 
for a possible role in giving rise to catalytic activity to a noncatalytic ADAM.  Glutamate 
and zinc were selected due to their currently known roles in nucleophilic attack.  
Experimentally, the importance of zinc and glutamate for catalytic activity exhibited by 
ADAMs has been shown in many studies via the utilization of EDTA, a chelator of zinc, 
and E/A active site mutants in which glutamate was substituted for an alanine residue. 
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EDTA and the E/A active site mutants, separately, abolished catalytic activity that was 
previously exhibited by wild-type catalytically active ADAMs. (Gaultier, 2002; Smith and 
DeSimone, 2002; Chesneau, 2003) 
The α2M trapping assay was modified to include increasing concentrations of 
glutamate and zinc (0-500μM).  This concentration range was chosen as it covers the 
physiological values as well as supra-physiological levels that could occur in enriched 
environments or potential disease states.  No catalytic activity was exhibited by wt 
ADAM7 PM-Fc at any concentration of zinc or glutamate tested (Fig 13B and 13C).  
These results demonstrate that the restored glutamate in the consensus active site of 
ADAM7 is essential for catalytic activity. 
Additionally, these data indicate a potential preservation of the overall catalytic 
architecture in a noncatalytic ADAM including, but not limited to, metal ion coordination 
and spatial arrangement to facilitate nucleophilic attack when given the consensus 
active site residues.  
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Figure 13.  Restoration of Active Site Elements Bestows Catalytic Activity to 
Human ADAM7.  A) α2-Macroglobulin trapping assay demonstrates catalytic activity 
via gel-shift.  ADAM28 PM-Fc wt and ADAM7 PM-Fc Q337/E exhibit catalytic activity, 
while ADAM7 PM-Fc wt did not.  B)  Trapping assay from panel A were repeated with 
“dead” wt ADAM7 to determine if an enriched glutamate environment produces 
catalytic activity in noncatalytic ADAMs.  C)  The effect of zinc concentration on 
ADAM7 wt catalytic activity was determined.  All images are representative of 3 
independent runs.  
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ADAM7 Q337/E Exhibits Catalytic Specificity Mirroring ADAM28  
The proposed gene duplication events that allowed ADAM7 to emerge as a 
potential regulator of ADAM28 likely maintained many properties and functions of 
ADAM28.  Indeed, the integrin ligand properties of ADAM7 are identical to those of 
ADAM28 (Bridges, 2005; Edwards, 2008).  As the ADAM7 mutant exhibited enzymatic 
activity, I wanted to determine if the catalytic properties specifically reflected those 
established for ADAM28 action.  If ADAM7 could be “awakened” via mutations within 
the catalytic active site of the metalloprotease domain and exhibit catalytic properties 
that closely resembled those established for ADAM28, it would provide another 
functional link to the ADAM7 ancestry and provide additional information on the first 
known “awakened” noncatalytic enzyme.   
ADAM28 cleaves myelin basic protein (MBP) at distinct sites (Howard, 2001).  I 
modified this assay to address if ADAM7 would catalyze the hydrolysis of MBP in the 
same manner as previously established for ADAM28.  Although other ADAMs, including 
ADAM10, are known to process MBP, each does so by producing unique cleavage 
products (Howard, 2001).  Interestingly, ADAM7 Q337/E activity towards MBP generated 
a similar fragment pattern as that obtained with the ADAM28 control (Fig 14).  Because 
these data are qualitative, we are pursuing N-terminal sequencing of the respective 
fragments to further establish a functional link between ADAM7 and ADAM28.  By 
demonstrating overlap in substrate specificity between ADAM28 and ADAM7, these 
results support our model that ADAM28 and ADAM7 are evolutionarily and functionally 
linked.  
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Figure 14.  Catalytic Specificity of ADAM7 Q
337
/E.  Myelin basic protein (MBP) 
cleavage assays demonstrate that the ADAM7 active site mutant qualitatively 
exhibits catalytic specificity mirroring ADAM28 wt.  Full-length, unprocessed MBP 
(~18 kDa) is denoted by the asterisks.  Arrows indicate MBP cleavage products.    
 
 
Discussion 
ADAMs are a family of proteases that have been implicated in many aspects of 
human health and disease through catalyzing ectodomain shedding, a process in which 
cell-surface substrates are liberated into soluble, biologically active derivatives.  While 
ADAM-mediated shedding is critical to the normal health state, including cardiac 
development (Zhou, 2004) and immune response (Gooz, 2010), dysregulation of 
ADAM-mediated shedding has been implicated in many pathological conditions, such 
as cardiac hypertrophy (Asakura, 2002) and chronic inflammatory states (Klein, 2010; 
Bzowska, 2004).  A better understanding of how ADAM-mediated ectodomain shedding 
is regulated could provide new therapeutic avenues for the deleterious conditions 
associated with abnormal ADAM activity.  A summary of known regulatory mechanisms 
of ADAM proteolytic action is available in Table 1.  Largely, these mechanisms are 
standard dogma to the field of enzymology.  Textbooks classically categorize regulation 
into inhibition, zymogen production, genetic control, feedback/feedforward allosteric 
control, and covalent modification (e.g. phosphorylation), and current knowledge 
regarding ADAM regulation does not greatly differ from these previously established 
mechanisms.   
My work is aimed at providing initial support for a previously unexplored 
regulatory mechanism involving noncatalytic ADAMs.  Noncatalytic ADAMs lack one or 
more consensus elements within the catalytic active site leading to a “dead” enzyme.  
Despite being noncatalytic, they have retained the complete domain architecture of their 
active counterparts (Liu, 2009), and exhibit functional activity (e.g. integrin binding) that 
is attributed to these specific nonenzymatic domains (Edwards, 2008).  My proposed 
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mechanism of noncatalytic ADAMs governing the availability of substrates could 
potentially alter the way enzyme regulation is viewed and open new therapeutic 
avenues for the treatment of pathologies associated with ADAM-mediated shedding by 
providing a new drug target, the noncatalytic ADAM.  To be feasible, this novel 
regulatory mechanism requires expression of noncatalytic ADAMs within the same 
niche as catalytically active counterparts to produce competition for binding partners.  
Through competition with catalytically active ADAMs, these noncatalytic ADAMs may 
effectively regulate the activity of their catalytically active counterparts by governing 
substrate availability or localization to the substrate through other molecular 
interactions, namely integrin binding.   
In the current proposal, ADAM7 and ADAM28 were used as a model system to 
initiate studies addressing the validity of our regulatory model.  ADAM28 is catalytically 
active and has been to play a role in various biological processes from transmigration of 
lymphocytes (McGinn, 2011) to TNF-α shedding (Jowett, 2012).  ADAM7 is 
noncatalytic, but is suggested to play a role in increased metastasis of melanoma cells 
(Wei, 2011).  ADAM28 and ADAM7 were chosen as my model pair due to the striking 
similarity of their disintegrin domain protein sequence and common binding partners, as 
well as the the possibility that ADAM7 may have arisen from ADAM28 via evolutionary 
events (Bates, 2002).  Initially, I set out to determine the expression patterns of ADAM7 
at the protein level utilizing ADAM7 monoclonal antibodies our lab had developed 
against the ADAM7 disintegrin domain.  Unfortunately, these antibodies did not 
recognize full-length ADAM7 exogenously expressed on the surface of multiple cell 
lines under the conditions tested.  This was confirmed in flow cytometry with intact cells 
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as well as with reduced and denatured isolated cell-surface protein via immunoblot.  At 
this point, it still remains to be determined if ADAM7 is expressed within the same 
cellular niche as ADAM28 in primary human cells or cell lines.  Our ADAM7 monoclonal 
antibodies are still in ascites, which is the fluid produced in the peritoneal cavity during 
production of the antibodies.  Future directions are to purify the antibodies from the 
ascites stage, as to reduce any potential contaminants in the supernatant, for a 
reduction in cross-reactivity and subsequent increased sensitivity to full-length ADAM7 
disintegrin domain.   
The second part of my thesis used ADAM7 to determine the magnitude of 
metalloprotease domain preservation and similarity to ADAM28.  An active site mutant, 
ADAM7 Q337/E, was developed in which the active site consensus element, glutamate, 
was restored via a single point mutation.  The restoration of glutamate provided ADAM7 
with an intact consensus sequence (HExxHxxGxxH) within the active site.   
Utilizing an α2M trapping assay, ADAM7 Q337/E was shown to exhibit catalytic 
activity, providing the first demonstration to my knowledge of “awakening” a dead 
protease through a single point mutation within the catalytic active site.  This was a very 
exciting result as it also provided the first evidence to suggest the gross structural 
preservation of the catalytic active site in the metalloprotease domain of noncatalytic 
ADAMs.  As only a single amino acid within the active site was altered, the data 
suggests the overall structural elements that facilitate substrate interactions were 
present and intact with the noncatalytic ADAM7.  Additionally, these data revealed for 
the first time that a noncatalytic ADAM’s metalloprotease domain has the ability to 
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interact known ADAM substrates, a key component of the proposed regulatory 
mechanism. 
Based upon the literature, it was feasible that increased concentrations of zinc or 
glutamate might account for the observed catalytic activity of ADAM7 (Kirsch, 1989; 
Kirsch 1992).  If wild type ADAM7 encounters environments enriched for zinc or 
glutamate in vivo, conditions could be favorable enough to induce ADAM7 to exhibit 
catalytic activity.  This concept embodies another potential regulatory mechanism of 
noncatalytic ADAMs.  In fact, it would suggest that noncatalytic ADAMs are indeed 
active in select circumstances.  However, upon modification of the α2M assay to include 
increasing concentrations of glutamate and Zn2+, catalytic activity was not exhibited by 
wild-type ADAM7.  These results further confirmed the role of active site consensus 
elements, particularly glutamate, and the effects of their restoration in a noncatalytic 
ADAM.   
Following the demonstration of general catalytic activity, I then examined the 
catalytic specificity exhibited by ADAM7 Q337/E.  Specificity of interactions between the 
metalloprotease domain and substrates provides crucial insight to further validating the 
proposed regulatory mechanism, as it may suggest the ability of a noncatalytic ADAM to 
interact with substrates via the metalloprotease domain.  Interaction in this manner 
between noncatalytic ADAMs and substrates, while not producing cleavage products, 
may still provide a means of competitive binding.  
Catalytic specificity of ADAM-mediated shedding was established using myelin 
basic protein (MBP), a well-known substrate of ADAM28 and other ADAMs (Howard, 
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2001).  As shown in figure 12, ADAM7 Q337/E appears to produce cleavage products of 
similar size to those produced by ADAM28, suggesting a similarity in catalytic 
specificity.   
 These results, as well as the preliminary data also discussed, have provided key 
evidence to support the potential for a regulatory mechanism in which noncatalytic 
ADAMs govern the availability of substrates in the presence of their catalytically active 
counterparts through competitive binding.  Additionally, by demonstrating previously 
unknown functions of noncatalytic ADAMs, these data have potentially opened the door 
to new areas of investigation: 
i)  How enzymatic regulation is viewed.  As previously discussed, the known 
regulatory mechanisms are centralized around active enzymes and substrates.  
However, now that a novel regulatory role involving noncatalytic ADAMs has been 
proposed and supported, investigation into the putative regulatory roles of other 
noncatalytic enzymes is merited.  One example, phospholipase C-related catalytically 
inactive protein (PRIP) has actually been shown to regulate lypolytic activity of 
hormone-sensitive lipase in adipose tissue via phosphatase translocation (Okumura, 
2014).  While this is not competitive binding of substrate, it still represents a regulatory 
mechanism in which a noncatalytic enzyme is regulating the activity of a catalytically 
active enzyme expressed within the same niche.   
ii) Restoration of catalytic activity.  A single point mutation bestowed catalytic 
activity to ADAM7.  This is a very novel observation and it remains to be determined if 
restoration of consensus elements within the active site can bestow catalytic activity to 
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other noncatalytic ADAMs.  While some noncatalytic ADAMs (ADAM7, ADAM29) are 
only lacking a single consensus element within the active site, others are lacking 
several (Wei, 2011).  In fact, ADAM11 has retained no recognizable consensus 
elements (Table 2).  Restoration of the elements in ADAM11, or another protease that 
may be lacking all required elements, would begin to answer how far removed these 
“dead” enzymes are from catalytic activity.  The ability to reproduce the effect observed 
with ADAM7 in another ADAM, especially one lacking many or all consensus elements, 
would provide further details regarding the preservation of the metalloprotease domain 
throughout evolutionary events.  Due to the presence of noncatalytic enzymes in 
multiple classes, the impact of exploring this feature of “raising the dead” has potentially 
broad implications across multiple disciplines. 
 
 
Conclusion 
In summary, I have demonstrated preservation of the gross structural integrity of 
the metalloprotease domain of noncatalytic ADAMs.  In doing so, the “awakened” 
ADAM7 displayed catalytic specificity qualitatively mirroring that of ADAM28.  Despite 
the inability to determine ADAM7 expression at the protein level, these results provide 
key data to support the existence of a role for noncatalytic ADAMs in regulating the 
shedding activity of their catalytically active counterparts by governing substrate 
accessibility and availability.   
 
 
Future Directions 
 Many follow-up experiments to the findings in my thesis will be pursued to 
provide additional evidence of our regulatory model.  With respect to the “walking dead” 
ADAM7 active site mutant, several approaches will be undertaken to provide additional 
data to my exciting preliminary findings.  Excising and analyzing the MBP cleavage 
products via N-terminal sequencing and mass spectrometry to determine the specific 
cleavage sites will provide definitive evidence of catalytic specificity of the ADAM7 
mutant as compared to ADAM28.   
 To further assess the structural similarities of the metalloprotease domain 
catalytic active site of ADAM7 and ADAM28, a series of modified α2M assays will be 
used.  Confirmation of catalytic activity of ADAM7 Q337/E via metalloprotease 
components will be determined using broad spectrum inhibitors.  Among those to be 
used are chelators, EDTA/EGTA and 1,10-phenanthroline, as well as inhibitors of 
various protease types, such as Aprotinin, PMSF, Pepstatin A, Pefabloc-SC, and 
Leupeptin. We expect only the chelators to abolish catalytic activity.  To verify this, and 
that they are working through chelation as opposed to competitive binding, Zn2+ will be 
added in excess in the presence of the chelators to rescue catalytic activity.  A pitfall of 
this is the single aspartate residue following the final histidine within the consensus 
sequence of the catalytic active site, which could potentially play a role in catalytic 
activity, as occurs via aspartate proteases.  This will be determined using Pepstatin A, 
which is an inhibitor of aspartate proteases. 
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 Following use of the broad spectrum inhibitors, a series of physiologically 
relevant metalloprotease inhibitors will be used.  Tissue Inhibitor of Metalloproteases 
(TIMPs) are a family of metalloprotease inhibitors used extracellularly to regulate the 
activity of Matrix Metalloproteases (MMPs) and ADAMs to maintain a homeostatic 
environment.  Four members of the TIMP family are known, with three (TIMP-1, TIMP-3, 
and TIMP-4) displaying activity toward the ADAMs.  TIMPs abolish catalytic activity in a 
two-step inhibition mechanism in which they chelate metal cations, followed by 
competitive binding within the catalytic active site.  The use of TIMP-1, TIMP-2, and 
TIMP-3 in a modified α2M trapping assay with ADAM28 and ADAM7 Q337/E will further 
assess catalytic activity resulting from metalloprotease components, as well as potential 
catalytic active site similarity between ADAM7 and ADAM28.  We expect ADAM7 Q337/E 
to be inhibited by TIMP-3, but not TIMP-1 and TIMP-2, as that is the established pattern 
of inhibition of ADAM28 via TIMPs.  Pitfalls of this study include the inability of TIMP-3 
to inhibit ADAM7 Q337/E, as well as inhibition of the awakened ADAM7 mutant by TIMP-
1 and/or TIMP-2.  Differences of inhibition patterns would demonstrate a structural 
difference among the catalytic active site and metalloprotease domain of ADAM7 and 
ADAM28, however we do not expect that to occur.   
Additionally, the ADAM7 active site mutant and ADAM28 will be used in a series 
of assays designed to investigate catalytic efficiency and binding affinity via the 
metalloprotease domain with significant contributions from Dr. Tonya Zeczycki.  
Obtaining kinetic measurements of the ADAM7 mutant to compare with the kinetic 
properties of ADAM28 will provide further evidence as to the similarity of the catalytic 
active site in the metalloprotease domain of catalytically active and noncatalytic ADAMs.  
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Determining binding affinity (KD) of these enzymes would provide significant insight into 
how the potential regulation occurs.  It is unknown how much noncatalytic ADAM would 
need to be expressed to yield an inhibitory effect.  This is likely to be contingent on how 
avid the noncatalytic ADAMs bind substrate and/or receptors as compared to catalytic 
counterparts.  The ADAM7 mutant characterized here would allow for such approaches.  
In addition, a soluble cell-binding assay to investigate integrin binding kinetics would be 
worthwhile.  For determination of the KD of ADAM7 and ADAM28 for integrin receptors, 
a modified version of the assay shown in Figure 5 will be run in which fluorescently 
conjugated ADAM ligands are used to generate standard curves correlating protein 
quantity to fluorescent intensity.  Unlabeled competitors (ADAM7), as well as 
noncompetitive controls such as ADAM29, will be titrated in for determining competitive 
inhibition (Ki).    
The ability of a noncatalytic ADAM to competitively inhibit a catalytically active 
counterpart will be assessed using a breast cancer cell line, MDA-MB231.  ADAM28 
cleavage of insulin-like growth factor binding protein-3 (IGFBP-3) into distinguishable 
products is detectable using established reagents in various techniques.  Exogenous 
ADAM7 expression is expected to decrease ADAM28-mediated shedding of IGFBP-3 
via competitive inhibition.  These expected results would provide further evidence 
indicating the ability of a noncatalytic ADAM to competitively bind substrate in the 
presence of a catalytically active counterpart.  Additionally, exogenous expression of 
ADAM7 Q337/E is expected to increase IGFBP-3 shedding, which would be indicative of 
an overlap in substrate recognition and, potentially, catalytic specificity.  
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Next, it would be crucial to identify expression patterns of ADAM7 at the protein 
level.  As previously mentioned, purification of the hybridoma supernatant may be 
required to reduce cross-reactivity and increase selectivity toward ADAM7.  
Optimization of techniques, including flow cytometry and immunohistochemistry, would 
provide multiple avenues of ADAM7 detection on the cell surface.  Upon establishing 
ADAM7 expression at the cell surface, ADAM28 expression should then be confirmed.  
The expression patterns, along with the kinetic studies, would provide necessary data to 
confirm the existence of a regulatory model involving noncatalytic ADAMs.   
Finally, outside of the proposed regulatory role, phylogenetic analyses of 
noncatalytic ADAM metalloprotease domain active sites would address the question if 
these ADAMs truly arose from their catalytically active counterparts or if they actually 
arose from a single, noncatalytic ancestor.  For this, Dr. Tyra Wolfsberg, of the National 
Human Genome Research Institute at NIH, has agreed to collaborate with our lab to 
conduct these studies.  With Dr. Wolfsberg’s assistance, the knowledge gap 
surrounding noncatalytic ADAMs could be closed significantly.   
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